These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21642950)

  • 1. Propofol and arrhythmias: two sides of the coin.
    Liu Q; Kong AL; Chen R; Qian C; Liu SW; Sun BG; Wang LX; Song LS; Hong J
    Acta Pharmacol Sin; 2011 Jun; 32(6):817-23. PubMed ID: 21642950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arctigenin, a potential anti-arrhythmic agent, inhibits aconitine-induced arrhythmia by regulating multi-ion channels.
    Zhao Z; Yin Y; Wu H; Jiang M; Lou J; Bai G; Luo G
    Cell Physiol Biochem; 2013; 32(5):1342-53. PubMed ID: 24280730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safe single-dose administration of propofol in patients with established Brugada syndrome: a retrospective database analysis.
    Flamée P; De Asmundis C; Bhutia JT; Conte G; Beckers S; Umbrain V; Verborgh C; Chierchia GB; Van Malderen S; Casado-Arroyo R; Sarkozy A; Brugada P; Poelaert J
    Pacing Clin Electrophysiol; 2013 Dec; 36(12):1516-21. PubMed ID: 23952345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial gap junctions: targets for novel approaches in the prevention of life-threatening cardiac arrhythmias.
    Tribulová N; Knezl V; Okruhlicová L; Slezák J
    Physiol Res; 2008; 57 Suppl 2():S1-S13. PubMed ID: 18373398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propofol: a safe anaesthetic drug in experimental cardiac surgery in rabbits.
    Giuliani E; Manenti A; Barbieri A; Farinetti A; Mattioli AV
    Ann Ital Chir; 2018; 89():92-94. PubMed ID: 29629881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gap junctions enhancer combined with Vaughan Williams class III antiarrhythmic drugs, a promising antiarrhythmic method?
    Li LD; Zhang CT; Ruan L; Ni MK; Quan XQ
    Med Hypotheses; 2011 Jan; 76(1):119-21. PubMed ID: 20889260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of gap junction channel in the development of beat-to-beat action potential repolarization variability and arrhythmias.
    Magyar J; Banyasz T; Szentandrassy N; Kistamas K; Nanasi PP; Satin J
    Curr Pharm Des; 2015; 21(8):1042-52. PubMed ID: 25354184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic therapy in atrial fibrillation.
    Ravens U
    Pharmacol Ther; 2010 Oct; 128(1):129-45. PubMed ID: 20624425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of frequency-dependent protocols in antiarrhythmic and proarrhythmic drug testing.
    Nánási PP; Szabó Z; Kistamás K; Horváth B; Virág L; Jost N; Bányász T; Almássy J; Varró A
    Prog Biophys Mol Biol; 2020 Nov; 157():76-83. PubMed ID: 31726065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propofol infusion syndrome: an overview of a perplexing disease.
    Fodale V; La Monaca E
    Drug Saf; 2008; 31(4):293-303. PubMed ID: 18366240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Potassium channels and arrhythmia].
    Funck-Brentano C
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():9-13. PubMed ID: 1307198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New class III antiarrhythmic drugs.
    Katritsis D; Camm AJ
    Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug development for treatment of cardiac arrhythmias: targeting the gap junctions.
    Wit AL; Duffy HS
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H16-8. PubMed ID: 17890421
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of N-(3,5-bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4-methoxybenzenesulfamide (sulcardine) as a novel anti-arrhythmic agent.
    Bai DL; Chen WZ; Bo YX; Dong YL; Kang AL; Sun WK; Wang W; Hu ZL; Wang YP
    Acta Pharmacol Sin; 2012 Sep; 33(9):1176-86. PubMed ID: 22922342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel pharmacological approaches for antiarrhythmic therapy.
    Ravens U
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):187-93. PubMed ID: 20082192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proarrhythmic events.
    Zipes DP
    Am J Cardiol; 1988 Jan; 61(2):70A-76A. PubMed ID: 3276126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of physiological late Na
    El-Bizri N; Li CH; Liu GX; Rajamani S; Belardinelli L
    Am J Physiol Heart Circ Physiol; 2018 Feb; 314(2):H236-H245. PubMed ID: 28971840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.